CHALLENGE
- An emerging Life Sciences company developing a treatment hoped to address an ultra rare, metabolic, genetic disorder
- This patient community was fragmented without a patient advocacy organization
- This patient community was fragmented without a patient advocacy organization
- Company didn’t have anywhere to query patients when seeking input for natural history study, clinical trial design, etc.